Consun Pharmaceutical Launches HKD200 Million Share Repurchase Program

Consun Pharmaceutical Group Ltd. ( (HK:1681) ) has provided an update.

Consun Pharmaceutical Group Ltd. has announced a share repurchase program, utilizing a general mandate granted by shareholders. The program aims to repurchase up to HKD200 million worth of shares from the open market, reflecting the company’s confidence in its business prospects and belief that its current share price undervalues its intrinsic worth. This initiative is aligned with the company’s long-term strategy to optimize capital structure and enhance shareholder value, while maintaining sufficient financial resources for ongoing operations.

The most recent analyst rating on (HK:1681) stock is a Buy with a HK$10.00 price target. To see the full list of analyst forecasts on Consun Pharmaceutical Group Ltd. stock, see the HK:1681 Stock Forecast page.

More about Consun Pharmaceutical Group Ltd.

Consun Pharmaceutical Group Ltd. operates in the pharmaceutical industry, focusing on the development and production of pharmaceutical products. The company is known for its commitment to enhancing its market position and optimizing its capital structure.

Average Trading Volume: 2,298,188

Technical Sentiment Signal: Buy

Current Market Cap: HK$9.54B

See more insights into 1681 stock on TipRanks’ Stock Analysis page.